Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments (opens in new tab)

The collaboration, launched through a multi-target discovery collaboration and license agreement, is designed to combine Merck’s global expertise in discovering novel therapeutics with Protillion’s Prot-MaP™ on-chip antibody discovery platform, short for Protein Display on a Massively Parallel Array. The post appeared first on .